ArchiMed
ARCHIMED is a global private equity firm exclusively dedicated to healthcare industries, founded in 2014 in Lyon, France, managing over $15 billion across multiple healthcare-focused buyout funds and operating from offices in Europe, North America, and Asia.
- Company typePrivate
- Founded2014
- HeadquartersLyon, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ArchiMed does
ARCHIMED is a global private equity firm exclusively dedicated to healthcare industries, founded in 2014 and headquartered in Lyon, France (registered as ARCHIMED SAS with the French AMF under N° GP-14000002). The firm manages over $15 billion in assets under management as of mid-2026 across a family of dedicated healthcare buyout funds — MED I (€150M, 2014), MED II (€315M, 2017), MED Platform I (€1.5B, 2020), MED III (€650M, 2021), MED Platform II (€3.5B, 2023), and MED Rise (€400M, 2024) — spanning small-cap and mid-market transactions. ARCHIMED employs 160+ professionals composed of one-third finance, one-third scientists, and one-third operational profiles, organized into internal sector teams covering seven priority healthcare areas: Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech.
The firm deploys a proprietary operating platform combining MedValue (value-creation levers including internationalization, innovation, product range expansion, and bolt-on M&A), MedSeg (a sector analysis tool mapping 430 sub-segments), MedDiscover (deal-sourcing tools and processes), the ARCHIMED BUSINESS SYSTEM (ABS operating playbook covering governance, processes, talent, and continuous improvement), the MedTalents® network of 200+ senior healthcare professionals, and tailored ESG/Sustainability Roadmaps for portfolio companies. ARCHIMED's business model is standard private equity: it earns recurring management fees as a percentage of committed/invested capital across its registered funds, plus performance-based carried interest on successful realizations — historical exits include a 300x return on Polyplus (sold to Sartorius Stedim in 2023), 7.2x on MED I overall, 5x on Ad-Tech (Nihon Kohden, 2024), 4.5x on Vita Health (2023), and 6x on EUROLyser (Antech Diagnostics, 2022). Capital is sourced from external institutional limited partners (LPs), with offices in Lyon (European HQ), New York, Tokyo, and Singapore supporting transatlantic and transpacific deal activity across majority buyouts, take-privates, and buy-and-build platforms.
ArchiMed firmographics
Firmographics- Name
- ArchiMed
- Legal name
- ARCHIMED SAS
- Website
- https://archimed.group
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ARCHIMED is a global private equity firm exclusively dedicated to healthcare industries, founded in 2014 in Lyon, France, managing over $15 billion across multiple healthcare-focused buyout funds and operating from offices in Europe, North America, and Asia.
- Ownership category
- akta.pro rank
Where ArchiMed is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Markets served
ArchiMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Revenue model
- Private equity fund management fees: As a registered French asset management company (AMF N° GP-14000002) managing multiple buyout funds (MED I, MED II, MED III, MED Platform I, MED Platform II, MED Rise, MED Bio, MED Access), ARCHIMED earns recurring management fees typically calculated as a percentage of committed or invested capital across its various healthcare-focused funds.
- Carried interest / investment returns: Performance-based economics earned on successful realizations of portfolio companies. ARCHIMED's historical realizations include 300x on Polyplus, 5x on Ad-Tech (MED II), 6x on EUROLyser (MED II), 4.5x on Vita Health (MED I), 4x on Fytexia (MED I), 3x on Primo Group (MED I), 7.2x on Citieffe/MED I (59% IRR), and 4.6x on Diesse (MED II).
- Value-creation services to portfolio companies: Operational, medical, scientific and financial advisory provided to portfolio companies (MedValue playbook) for which ARCHIMED is compensated indirectly via its equity stake and indirectly through management fees / carried interest.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | PE fund commitments with management fees and carried interest (not publicly disclosed) |
Go-to-market motion1 record
ArchiMed product offering
Product offeringCore offering
ArchiMed is a global private equity firm dedicated exclusively to the healthcare industry, raising and managing multiple buyout funds (MED I, MED II, MED III, MED Platform I, MED Platform II, MED Rise) that deploy capital through majority buyouts, take-privates, and buy-and-build platforms. The firm targets European and North American small-cap (€5M–€30M equity) and mid-cap (€100M–€1B equity) healthcare companies, providing them with capital, operational support, and sector expertise to accelerate internationalization, innovation, and growth.
Differentiator
Problem solved
Functional benefit
Brands
- ARCHIMED Diagnostics: Internal ARCHIMED sector team focused on diagnostics investments (Stago, ARK Diagnostics)
- ARCHIMED Healthcare IT
- ARCHIMED Life Science Tools & Services
- ARCHIMED MedTech
- ARCHIMED Pharma Services
- EURÊKA Foundation
Products and services
- MED I Fund ArchiMed's inaugural €150 million small-cap healthcare buyout fund raised in 2014; partners with growth companies in European and North American small-cap healthcare sectors via majority stakes of €5 million to €30 million. Ranked best performing 2014 vintage global buyout fund per Preqin (7.2x MOIC, 59% IRR over 11 years). Fully realized with final exit (Citieffe) in November 2025.
- MED II Fund ArchiMed's €315 million small-cap healthcare growth buyout fund (raised 2017, invested 2018); targets European and North American small-cap healthcare companies via majority stakes of €5 million to €30 million. Top 5% performer for 2018 vintage. Invested in 10+ platforms including ActiGraph/Ametris, Ad-Tech, NAMSA, EUROLyser, Micromed, Citieffe, Diesse, Primo.
- MED III Fund ArchiMed's €650 million small-cap healthcare growth fund (closed August 2021); partners with European and North American small-cap healthcare companies via majority stakes in association with existing owners and managers. Cardioline (cardiology telemedicine) was the first investment.
- MED Platform I Fund ArchiMed's mid-market buy-and-build platform fund (closed at €1.5 billion in August 2020, then a record for a European-headquartered PE healthcare group); partners with growth companies in European and North American mid-cap healthcare via majority stakes for €50 million to €1 billion in association with existing owners and managers. Now fully invested, with platforms including SUANFARMA, CARSO, DHG, NAMSA, Stragen, Bomi Group.
- MED Platform II Fund ArchiMed's €3.5 billion successor mid-market buyout fund (closed June 2023, more than 2x oversubscribed); partners with European and North American mid-cap healthcare growth companies via majority stakes for €100 million to €500 million in association with existing owners and managers. Approximately 70% invested after Stago transaction.
- MED Rise Fund ArchiMed's €400 million small-cap healthcare fund (closed April 2024 at hardcap); invests in small-cap healthcare companies including Rivadis, Arkstone, SeqCenter, FIM Medical, and IRAB. Top quartile performer for its vintage year.
- ARCHIMED Investor Portal Secure investor data platform hosted on Intralinks (https://iam.intralinks.com/idp/login/) provided to ArchiMed's Limited Partners for accessing fund documentation, due diligence materials, and investor reporting including EU SFDR pre-contractual disclosures (Annex II/III).
Companies that use ArchiMed
Customer profileIdeal customer profiles2 records
ArchiMed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability8 records
Feature5 records
ArchiMed partnerships and signals
Strategic signalRecent moves12 records
Expansion highlights6 records
ArchiMed competitors and assessment
Company assessmentDirect peers
- EQT Life Sciences: EQT's dedicated healthcare and life sciences investing arm (formerly LSP), managing multi-billion euro funds focused on healthcare buyouts, growth, and venture across Europe — direct comparable to ARCHIMED in scale, geography, and sector specialization.
- Bain Capital Life Sciences: Bain Capital's dedicated life sciences franchise invests across pharma, biotech, MedTech, and healthcare services globally — directly comparable to ARCHIMED in healthcare-only focus, multi-fund strategy, and transatlantic deal flow.
- Avista Capital Partners: U.S.-based healthcare-dedicated middle-market PE firm investing across MedTech, pharma services, and consumer health — closely comparable to ARCHIMED in sector focus, deal size range ($50-500M), and buyout strategy.
- Linden Capital Partners: Chicago-based PE firm exclusively focused on healthcare (medical products, pharma services, consumer health) with $5B+ AUM — directly comparable to ARCHIMED as a healthcare-only middle-market buyout specialist.
- Water Street Healthcare Partners: Dedicated healthcare PE firm investing across MedTech, diagnostics, specialty pharma, and healthcare services — comparable to ARCHIMED in sector specialization and mid-market deal sizing.
- Welsh, Carson, Anderson & Stowe: Long-standing U.S. healthcare-focused PE firm investing in growth and buyout opportunities across services, MedTech, and life sciences — directly comparable to ARCHIMED in healthcare-only focus and LP base of institutional investors.
Broad incumbents
- Carlyle Group Healthcare: One of the largest global alternative asset managers with a dedicated healthcare team executing buyouts across MedTech, pharma services, and healthcare IT — broader portfolio than ARCHIMED but directly competitive on healthcare-only deals at scale.
- KKR Health Care Strategic Growth: KKR's healthcare vertical invests across MedTech, pharma, and healthcare services globally with multi-billion dollar funds — competes with ARCHIMED on mid-market healthcare buyouts but operates within a much broader PE platform.
- Apax Partners (Healthcare): Global PE firm with a major healthcare vertical (Apax Health) executing European and global healthcare buyouts — directly competitive with ARCHIMED on transatlantic mid-market healthcare deals despite broader sector remit.
- Permira (Healthcare/Life Sciences): European-headquartered global PE firm with healthcare investing as a key vertical — comparable to ARCHIMED in geographic base (European HQ, transatlantic deal flow) and mid-market healthcare deal sizing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights6 records
Customer concentration
ArchiMed social profiles
Digital presenceArchiMed compliance and trust
Trust signalCompliance9 records
ArchiMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
ArchiMed leadership team
Management profileNumber of profiles
Profiles14 records
ArchiMed subsidiaries and ownership
Company hierarchySubsidiaries6 records
ArchiMed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ArchiMed M&A and investment
M&A and investmentM&A40 records
Investments8 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ArchiMed
What does ArchiMed do?
ArchiMed is a global private equity firm dedicated exclusively to the healthcare industry, raising and managing multiple buyout funds (MED I, MED II, MED III, MED Platform I, MED Platform II, MED Rise) that deploy capital through majority buyouts, take-privates, and buy-and-build platforms. The firm targets European and North American small-cap (€5M–€30M equity) and mid-cap (€100M–€1B equity) healthcare companies, providing them with capital, operational support, and sector expertise to accelerate internationalization, innovation, and growth.
Is ArchiMed a public or private company?
ArchiMed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ArchiMed founded?
ArchiMed was founded in 2014. It employs 1 to 10 people.
Where is ArchiMed based?
ArchiMed is headquartered in Lyon, France, in the Europe region.
How does ArchiMed make money?
Three revenue lines are on record. Private equity fund management fees are the primary driver. The others are carried interest / investment returns and value-creation services to portfolio companies.
Who are ArchiMed's main competitors?
Direct peers on record are EQT Life Sciences, Bain Capital Life Sciences, Avista Capital Partners, Linden Capital Partners, Water Street Healthcare Partners and Welsh, Carson, Anderson & Stowe. Broad incumbents are Carlyle Group Healthcare, KKR Health Care Strategic Growth, Apax Partners (Healthcare) and Permira (Healthcare/Life Sciences).
Does ArchiMed have an API?
No public API is recorded for ArchiMed.